Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : 2-FMA or Adalimumab or Codeine

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
None (2) · (multiple, generic dominant) (1) · Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada (1)
classes:
Amphetamine (1) · Analgesic (2) · Opioid (2) · Prodrug (1) · Research material (1) · Stimulant (1) · [[:Category:Biologics|Biologic]] (1) · [[:Category:DMARDs|DMARD]] (1) · [[:Category:Immunosuppressants|Immunosuppressant]] (1) · [[:Category:Monoclonal_antibodies|Monoclonal antibody (fully human IgG1)]] (1) · [[:Category:TNF_inhibitors|TNF-α inhibitor]] (1)
mechanism:
Monoamine releasing agent (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. (1)
uses:
None (3) · Mild to moderate pain; cough suppression (low-dose). (1)
starting dose:
None (2) · 40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1) · Adult: 15–60 mg every 4 hours as needed. (1)
preparations:
None (2) · 40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (2) · 360 mg/day (1) · 40 mg every week (selected indications); otherwise 40 mg every other week (1)
routes:
None (2) · PO (only formulation marketed in the US). (1) · Subcutaneous (1)
onset:
None (2) · 30–60 min (PO) (1) · Symptomatic effect within weeks; full response by 12-24 weeks (1)
duration:
None (2) · 2 weeks per dose (1) · 4–6 hours (1)
halflife:
None (2) · 2.5–3 hours (1) · ~14 days'"`UNIQ--ref-00001103-QINU`"' (1)
bioavailability:
None (2) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' (1)
pregnancy:
None (3) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)
legal:
None (3) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)

Showing below up to 4 results in range #1 to #4.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"